Schonfeld Strategic Advisors LLC Trims Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Schonfeld Strategic Advisors LLC trimmed its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 7.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 62,977 shares of the company’s stock after selling 5,266 shares during the quarter. Schonfeld Strategic Advisors LLC owned 0.17% of iTeos Therapeutics worth $484,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. increased its position in iTeos Therapeutics by 1.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company’s stock valued at $4,771,000 after purchasing an additional 5,368 shares during the period. Marquette Asset Management LLC bought a new position in shares of iTeos Therapeutics in the 4th quarter worth $122,000. Clear Harbor Asset Management LLC purchased a new stake in shares of iTeos Therapeutics during the 4th quarter worth $96,000. SG Americas Securities LLC raised its holdings in iTeos Therapeutics by 12.2% in the fourth quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock worth $106,000 after purchasing an additional 1,508 shares in the last quarter. Finally, Empowered Funds LLC lifted its position in shares of iTeos Therapeutics by 5.0% during the fourth quarter. Empowered Funds LLC now owns 69,072 shares of the company’s stock valued at $530,000 after buying an additional 3,305 shares during the last quarter. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Stock Performance

ITOS stock opened at $6.68 on Friday. iTeos Therapeutics, Inc. has a one year low of $4.80 and a one year high of $18.70. The firm has a market cap of $255.67 million, a PE ratio of -2.12 and a beta of 1.39. The firm’s fifty day moving average is $6.55 and its 200 day moving average is $7.44.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings data on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.14. Research analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ITOS. Wells Fargo & Company lowered their price objective on iTeos Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research report on Tuesday, April 29th. JPMorgan Chase & Co. lowered their target price on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday, March 6th. Wedbush reaffirmed an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. Finally, HC Wainwright restated a “buy” rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a research note on Thursday, March 6th.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.